12:00 AM
 | 
Aug 01, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Jakafi: Phase III data

Top-line data from the open-label, crossover, international Phase III RESPONSE-2 trial in 149 PV patients who were resistant to or intolerant of hydroxyurea, who were dependent on phlebotomy for hematocrit control and who did not have enlarged spleens showed that twice-daily oral Jakafi met the primary endpoint of a greater proportion of patients who achieved hematocrit control at week 28 vs. best available therapy (62.2% vs. 18.7%, p<0.0001). Jakafi also met the secondary endpoints of a greater proportion of patients who...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >